Literature DB >> 15056382

The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins.

Barbara A Fernie-King1, David J Seilly, Peter J Lachmann.   

Abstract

Streptococcal inhibitor of complement (SIC) is a 31 kDa extracellular protein produced by a few highly virulent strains of Streptococcus pyogenes (in particular the M1 strain). It has been shown additionally to inhibit four further components of the mucosal innate response-lysozyme, secretory leucocyte proteinase inhibitor, human alpha-defensin 1 and the cathelicidin LL-37 which are all bactericidal against Group A Streptococci (GAS). We now show that SIC also inhibits variably the antibacterial action of hBD-1, -2 and -3. By enzyme-linked immunosorbent assay (ELISA), SIC binds strongly to hBD-2 and hBD-3, but not at all to hBD-1. Investigation of the antimicrobial action of beta-defensins hBD-1, -2 and -3 against GAS in two different buffer systems shows that both the killing efficiencies of all three defensins, and the binding of SIC to them, occurs more efficiently in 10 mm Tris buffer than in 10 mm phosphate. The lower ionic strength of the Tris buffer may underlie this effect. hBD-1 kills the M1 strain of GAS only in 10 mm Tris, but is able to kill an M6 (SIC negative) strain in 10 mm phosphate. The inhibition of hBD-3 by SIC is clearly of physiological relevance, that of hBD-2 is likely to be so, but the inhibition of hBD-1 occurs only at lower ionic strength than is likely to be encountered in vivo. Elastase digestion of SIC yields three major fragments of MW 3.843 kDa comprising residues 1-33 (fragment A); 10.369 kDa comprising residues 34-126 (fragment B); and MW 16.487 kDa, comprising residues 127-273 (fragment C). By ELISA, only fragment B binds to hBD-2 and hBD-3 and this may indicate the inhibitory portion of the SIC molecule.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056382      PMCID: PMC1782441          DOI: 10.1111/j.0019-2805.2004.01837.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

Review 1.  A review of saliva: normal composition, flow, and function.

Authors:  S P Humphrey; R T Williamson
Journal:  J Prosthet Dent       Date:  2001-02       Impact factor: 3.426

Review 2.  Group A Streptococcus: allelic variation, population genetics, and host-pathogen interactions.

Authors:  S D Reid; N P Hoe; L M Smoot; J M Musser
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.

Authors:  B A Fernie-King; D J Seilly; C Willers; R Würzner; A Davies; P J Lachmann
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 4.  [beta]-defensins in lung host defense.

Authors:  Brian C Schutte; Paul B McCray
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

5.  Nonpolar inactivation of the hypervariable streptococcal inhibitor of complement gene (sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonization.

Authors:  S Lukomski; N P Hoe; I Abdi; J Rurangirwa; P Kordari; M Liu; S J Dou; G G Adams; J M Musser
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

6.  Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands.

Authors:  M Mathews; H P Jia; J M Guthmiller; G Losh; S Graham; G K Johnson; B F Tack; P B McCray
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic.

Authors:  J Harder; J Bartels; E Christophers; J M Schroder
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

8.  Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics.

Authors:  N P Hoe; P Kordari; R Cole; M Liu; T Palzkill; W Huang; D McLellan; G J Adams; M Hu; J Vuopio-Varkila; T R Cate; M E Pichichero; K M Edwards; J Eskola; D E Low; J M Musser
Journal:  J Infect Dis       Date:  2000-10-03       Impact factor: 5.226

9.  Distribution of streptococcal inhibitor of complement variants in pharyngitis and invasive isolates in an epidemic of serotype M1 group A Streptococcus infection.

Authors:  N P Hoe; J Vuopio-Varkila; M Vaara; D Grigsby; D De Lorenzo; Y X Fu; S J Dou; X Pan; K Nakashima; J M Musser
Journal:  J Infect Dis       Date:  2001-01-17       Impact factor: 5.226

10.  Bactericidal activity of mammalian cathelicidin-derived peptides.

Authors:  S M Travis; N N Anderson; W R Forsyth; C Espiritu; B D Conway; E P Greenberg; P B McCray; R I Lehrer; M J Welsh; B F Tack
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

View more
  23 in total

1.  The beta-defensin gallinacin-6 is expressed in the chicken digestive tract and has antimicrobial activity against food-borne pathogens.

Authors:  Albert van Dijk; Edwin J A Veldhuizen; Stefanie I C Kalkhove; Johanna L M Tjeerdsma-van Bokhoven; Roland A Romijn; Henk P Haagsman
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Innate barriers against infection and associated disorders.

Authors:  Richard L Gallo; Victor Nizet
Journal:  Drug Discov Today Dis Mech       Date:  2008-06-01

3.  Structural evidence for lack of inhibition of fish goose-type lysozymes by a bacterial inhibitor of lysozyme.

Authors:  Peter Kyomuhendo; Inge W Nilsen; Bjørn Olav Brandsdal; Arne O Smalås
Journal:  J Mol Model       Date:  2008-05-20       Impact factor: 1.810

4.  Characterization of released polypeptides during an interferon-γ-dependent antibacterial response in airway epithelial cells.

Authors:  Mette Eliasson; Anders I Olin; Johan A Malmström; Matthias Mörgelin; Mikael Bodelsson; Mattias Collin; Arne Egesten
Journal:  J Interferon Cytokine Res       Date:  2012-08-21       Impact factor: 2.607

5.  Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva.

Authors:  Samuel A Shelburne; Chanel Granville; Maria Tokuyama; Izabela Sitkiewicz; Payal Patel; James M Musser
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus.

Authors:  Morgan A Pence; Suzan H M Rooijakkers; Anna L Cogen; Jason N Cole; Andrew Hollands; Richard L Gallo; Victor Nizet
Journal:  J Innate Immun       Date:  2010-09-01       Impact factor: 7.349

Review 7.  Molecular insight into invasive group A streptococcal disease.

Authors:  Jason N Cole; Timothy C Barnett; Victor Nizet; Mark J Walker
Journal:  Nat Rev Microbiol       Date:  2011-09-16       Impact factor: 60.633

8.  M1 protein allows Group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition.

Authors:  Xavier Lauth; Maren von Köckritz-Blickwede; Case W McNamara; Sandra Myskowski; Annelies S Zinkernagel; Bernard Beall; Partho Ghosh; Richard L Gallo; Victor Nizet
Journal:  J Innate Immun       Date:  2009-02-20       Impact factor: 7.349

9.  Cationic antimicrobial peptides disrupt the Streptococcus pyogenes ExPortal.

Authors:  Luis Alberto Vega; Michael G Caparon
Journal:  Mol Microbiol       Date:  2012-07-26       Impact factor: 3.501

10.  Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection.

Authors:  Tomas Fiedler; Catur Riani; Dirk Koczan; Kerstin Standar; Bernd Kreikemeyer; Andreas Podbielski
Journal:  Appl Environ Microbiol       Date:  2012-12-14       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.